The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Background The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a
milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic …

Background & Aims Treatment of liver cancer remains challenging because of a paucity of
drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is approved …

Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC) …

Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC
patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic …

In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic
acid derivatives that presented excellent in vitro xanthine oxidase inhibitory potency. As a …

Efficacy and Safety of apatinib in patients with intermediat... : Medicine Efficacy and Safety of
apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective …

We previously demonstrated that miR-29b-3p is a hopeful miRNA-based therapy against
colorectal cancer. In this study, we aimed to clarify a value of miR-29b-1-5p as a next …

Background Although large-scale, next-generation sequencing (NGS) studies of cancers
hold promise for enabling precision oncology, challenges remain in integrating NGS with …

Although MEK blockade has been highlighted as a promising antitumor drug, it has poor
clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have …